Kojic acid


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:12533912IVR1000 mg/kg 1000 mg/kgAffects iodine uptake into thyroidMetabolic endocrine-mediated perturbations
IVR1000 mg/kg 1000 mg/kgDecrease in T4 levelsMetabolic endocrine-mediated perturbations
IVR1000 mg/kg 1000 mg/kgIncrease in T3 levelsMetabolic endocrine-mediated perturbations
PMID:19483384IVR2 % 2 %Increased weights of adrenal glandMetabolic endocrine-mediated perturbations
IVR2 % 2 %Hyperplasia in thyroid glandMetabolic endocrine-mediated perturbations
IVR2 % 2 %Changes in adrenal gland morphologyMetabolic endocrine-mediated perturbations
IVR2 % 2 %Increased brain weightsNeurological endocrine-mediated perturbations
IVR2 % 2 %Affects skeletal developmentDevelopmental endocrine-mediated perturbations
IVR2 % 2 %Changes in liver morphologyHepatic endocrine-mediated perturbations
IVR2 % 2 %Increased testis weightsReproductive endocrine-mediated perturbations
IVR2 % 2 %Thyroid gland carcinomaEndocrine-mediated cancer;Metabolic endocrine-mediated perturbations
IVR2 % 2 %Increased liver weightsHepatic endocrine-mediated perturbations
IVR2 % 2 %Increased weights of thyroid glandMetabolic endocrine-mediated perturbations
IVR0.5 % 0.5 %Affects morphology of hepatocytesHepatic endocrine-mediated perturbations
IVR0.5 % 0.5 %Increased spleen weightsImmunological endocrine-mediated perturbations
IVR0.5 % 0.5 %Changes in liver morphologyHepatic endocrine-mediated perturbations
IVR0.5 % 0.5 %Increased weights of thyroid glandMetabolic endocrine-mediated perturbations
PMID:9734720IVR2 % 2 %Changes in morphology of thyroid glandMetabolic endocrine-mediated perturbations
IVR2 % 2 %Decrease in T3 levelsMetabolic endocrine-mediated perturbations
IVR2 % 2 %Increase in TSH levelsMetabolic endocrine-mediated perturbations
IVR3 % 3 %Increase in TSH levelsMetabolic endocrine-mediated perturbations
IVR3 % 3 %Changes in morphology of thyroid glandMetabolic endocrine-mediated perturbations
IVR3 % 3 %Decrease in T3 levelsMetabolic endocrine-mediated perturbations
IVR1.5 % 1.5 %Changes in morphology of thyroid glandMetabolic endocrine-mediated perturbations
IVR80 % 80 %Increase in TSH levelsMetabolic endocrine-mediated perturbations
IVR80 % 80 %Changes in morphology of thyroid glandMetabolic endocrine-mediated perturbations
IVR80 % 80 %Decrease in T3 levelsMetabolic endocrine-mediated perturbations
IVR8 % 8 %Decrease in T3 levelsMetabolic endocrine-mediated perturbations
IVR8 % 8 %Increase in TSH levelsMetabolic endocrine-mediated perturbations
IVR8 % 8 %Changes in morphology of thyroid glandMetabolic endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.